Ratio To Fine-Tune Radioligand Approach In Cancer With Trillium And Macropa Platforms

 
• By Ayisha Sharma

Emerging Company Profile: The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.  

Emerging Company Profile: Ratio Therapeutics
Ratio's Trillium Platform Helps Enhance Radioligand PK • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs